Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $1.06, $0.11 better than the analyst estimate of $0.95. Revenue for the quarter came in at $618 million versus the consensus estimate of $610.5 million.

Edwards Lifesciences sees FY2015 EPS of $4.00-$4.30, versus the consensus of $4.03. Edwards Lifesciences sees FY2015 revenue of $2.3-2.5 billion, versus the consensus of $2.4 billion.

For the first quarter of 2015, at current foreign exchange rates the company projects total sales to be between $570 million and $610 million, and diluted earnings per share, excluding special items, to be between $1.02 and $1.10.

(Street sees Q1 EPS of $0.92 on revenue of $583 million).

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.